Krystal Biotech Announces FDA Clearance Of Investigational New Drug Application For Kb408 For The Treatment Of Type 1 Alpha-1 Antitrypsin Deficiency
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech has announced that the FDA has cleared its Investigational New Drug application for KB408, a treatment for Type 1 Alpha-1 Antitrypsin Deficiency. Additionally, KB408 has been granted Orphan Drug Designation.
September 21, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Krystal Biotech's stock may see positive movement due to the FDA clearance of its new drug KB408 and the granting of Orphan Drug Designation.
FDA clearance of a new drug is a significant milestone for any biotech company, often leading to increased investor confidence and a potential rise in stock price. The granting of Orphan Drug Designation, which provides various incentives, further enhances the potential for positive impact on Krystal Biotech's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100